Dr. E. L. Stone

#PhD #Tcells #Immunotherapy #TumorImmunity #Immunology Tweets are my opinion, retweets not endorsement. Recovering academic. she/her. Now design Next-Gen CPIs.

[Dr. E. L. Stone @StoneEL2]

(4) Nextgen IL2s w reduced binding to CD25, induce less Treg proliferation and have had encouraging results in trials.

Our third-gen anti-CTLA-4 with limited ability to block CTLA-4 induces less Treg proliferation, has enhanced anti-tumor efficacy but reduced toxicity in models

[Dr. E. L. Stone @StoneEL2]

I was delighted to help reveal the first clinical data for GIGA-564, a differentiated, non-blocking anti-CTLA-4 mAb designed to selectively deplete intratumoral Tregs.

[Dr. E. L. Stone @StoneEL2]

https://t.co/DlK1wIbxQb

[Dr. E. L. Stone @StoneEL2]

#AACR2026 showcased how quickly oncology research is moving. It is inspiring to be surrounded by so many researchers working to better understand and hopefully treat cancer.

[Dr. E. L. Stone @StoneEL2]

https://t.co/74c94tu9n4

[Dr. E. L. Stone @StoneEL2]

Excited to be at @AACR to help share the first clinical data for GIGA-564, a differentiated, non-blocking anti-CTLA-4 mAb designed to deplete intratumoral Tregs, including a favorable safety profile and monotherapy RECISTv1.1 responses.

#AACR2026

https://t.co/DlK1wIbxQb

[Sergio Quezada @squezadd]

Absolutely honoured to be elected Fellow of the Academy of Medical Sciences together with amazing ⁦@ucl⁩ colleagues!! Thanks to ⁦⁦@uclcancer⁩ ⁦@CR_UK⁩ and my amazing team ⁦@QuezadaLab⁩ https://t.co/hJ4xtsY6r6

[Dr. E. L. Stone @StoneEL2]

@squezadd @ucl @uclcancer @CR_UK @QuezadaLab Congratulations! So highly deserved!

[Dr. E. L. Stone @StoneEL2]

I am excited to see where teamwork and following the science will lead this story next.

[Dr. E. L. Stone @StoneEL2]

This achievement has provided me with an opportunity to reflect on how we got here, and the story starts with following the science.

In 2009, I became interested in how FOXO1 regulates Ctla4, and how this regulation was a crucial component of FOXO1 function.

[Dr. E. L. Stone @StoneEL2]

Late last year, we announced IND Safe-to-Proceed for this molecule, and now, through cross-functional collaboration with teams across Grifols, GigaGen, and the NCI, this molecule is being tested in a Phase 1 study.

[Dr. E. L. Stone @StoneEL2]

https://t.co/iRlxkPARHj

Yesterday marked a significant milestone for our team at GigaGen, as we announced the dosing of the first participant in the Phase 1 study of GIGA-564.

[Dr. E. L. Stone @StoneEL2]

@Caroline_Bartma Why not the WBCs?

[Dr. E. L. Stone @StoneEL2]

You never know where following the science will take you.

In 2009 I became interested in the regulation of Ctla4 by FOXO1. In 2015 I decided to focus my new academic lab on understanding the multiple mechanisms of action of 1st gen anti-CTLA-4s.

https://t.co/GEXrp4fgKo

[Dr. E. L. Stone @StoneEL2]

https://t.co/wE0tBKrQ1E

It has been an honor to work on this molecule. Huge thanks to the entire team that made this milestone possible. And the biggest thanks of all to the patients who participate in clinical studies.